| ATMPs | Advanced Therapy Medicinal Products |
| CCL26 | Chemokine (C-C motif) ligand 26 |
| CCR2 | C-C Chemokine Receptor Type 2 |
| CDD | Cell Delivery Device |
| CDH5 | Cadherin 5 |
| COX | Cyclooxygenase |
| EC | Endothelial Cell |
| EGR-1 | Early Growth Response Protein 1 |
| EPC | Endothelial Progenitor Cells |
| ERK | Extracellular Signal-regulated Kinases |
| FABP 3 | Fatty Acid Binding Protein 3 |
| Glrx | Glutaredoxin-1 |
| GM-CSF | Granulocyte Macrophage-Colony-Stimulating Factor |
| GMP | Good Manufacturing Practice |
| GRP78 | 78-kD Glucose Regulated Protein |
| GSH adducts | S-Glutathionylation |
| HIF | Hypoxia Inducible Factor |
| HSC | Hematopoietic Stem Cells |
| IL-3 | Interleukin-3 |
| IL-8 | Interleukin-8 |
| i/nBZ | Ischemic/normoxic Border Zone |
| IFN γ | Interferon γ |
| M-CSF | Macrophage-Colony Stimulating Factor |
| MSC | Mesenchymal Stem Cells |
| MCP-1 | Monocyte Chemoattractant Protein-1 |
| MEGF10 | Multiple EGF-like-domains 10 |
| MI | Myocardial infarction |
| miR | MicroRNA |
| MIP-1 α | Macrophage Inflammatory Protein-1α |
| Mreg | Regulatory Macrophage |
| PAC | Circulating Proangiogenic Cell |
| PAD | Peripheral Arterial Disease |
| PCMO | Programmable Cell of Monocytic Origin |
| PDGF | Platelet Derived Growth Factor |
| PEG 2 | Prostaglandin E 2 |
| PI2/3K-Akt | Phosphoinositide 2/3-kinases-Akt signaling pathway |
| PI3K | Phosphoinositide 3-kinases |
| PTX 3 | Pentraxin Related Protein 3 |
| RIPC | Remote Ischemic Preconditioning |
| ROI | Region of Interest |
| SDF-1α | Stromal Cell-derived Factor-1α |
| SMC | Smooth Muscle Cells |
| VEGF | Vascular Endothelial Growth Factor |
| vWF | Von Willebrand Factor |
| Search terms | |
| ATMPs | Advanced Therapy Medicinal Products |
| Cardiovascular disease | |
| Cell delivery device | |
| Cell therapy | |
| Cell transplantation | |
| Cytotherapy | |
| Ischemic microenvironment | |
| Ischemia/reperfusion | |
| Myocardial infarction (MI) | |
| Peripheral arterial disease (PAD) | |
| Stem cell therapy | |